Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinghua Han

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Molecular Cancer|March 2, 2025
Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironmentMengting Wan, Shuaikang Pan, Benjie Shan, et al.
Cancer Cell International|November 3, 2018
Paraoxonase 3 is involved in the multi-drug resistance of esophageal cancerDabing Huang, Yong Wang, Yifu He, et al.
Breast Cancer Research : BCR|May 1, 2025
Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysisMenghao Dong, Jian Chen, Nannan Lu, et al.
Frontiers in Cell and Developmental Biology|April 8, 2025
Estrogen-induced FXR1 promotes endocrine resistance and bone metastasis in breast cancer via BCL2 and GPX4Yinzhong Shang, Tingfang Cao, Xin Ma, et al.
Nature Communications|March 17, 2022
Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosisMingming Wu, Xiao Zhang, Weijie Zhang, et al.
Cancer Cell|October 24, 2025
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 studyJia Zhong, Lin Wu, Zhengbo Song, et al.
The Lancet. Oncology|July 1, 2026
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trialHerui Yao, Qingyuan Zhang, Huiping Li, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Molecular Cancer|March 2, 2025
Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironmentMengting Wan, Shuaikang Pan, Benjie Shan, et al.
Cancer Cell International|November 3, 2018
Paraoxonase 3 is involved in the multi-drug resistance of esophageal cancerDabing Huang, Yong Wang, Yifu He, et al.
Breast Cancer Research : BCR|May 1, 2025
Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysisMenghao Dong, Jian Chen, Nannan Lu, et al.
Frontiers in Cell and Developmental Biology|April 8, 2025
Estrogen-induced FXR1 promotes endocrine resistance and bone metastasis in breast cancer via BCL2 and GPX4Yinzhong Shang, Tingfang Cao, Xin Ma, et al.
Nature Communications|March 17, 2022
Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosisMingming Wu, Xiao Zhang, Weijie Zhang, et al.
Cancer Cell|October 24, 2025
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 studyJia Zhong, Lin Wu, Zhengbo Song, et al.
The Lancet. Oncology|July 1, 2026
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trialHerui Yao, Qingyuan Zhang, Huiping Li, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
Pageof 7